DOCSLIB.ORG

Study the Toxicity and Anticancer Activity of Some New Amic Acid and Their Derivatives of Mefenamic Acid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Study the Toxicity and Anticancer Activity of Some New Amic Acid and Their Derivatives of Mefenamic Acid 642 Indian Journal of Forensic Medicine & Toxicology, January-March 2020, Vol.DOI 14, No.Number: 1 10.37506/v14/i1/2020/ijfmt/192974 Study the Toxicity and Anticancer activity of Some New Amic Acid and Their Derivatives of Mefenamic acid Ali A. Sabah1, Muna S. Al-Rawi1, Jumbad H. Tomma1 1Department of Chemistry, College of Education for Pure Science Ibn Al- Haitham, University of Baghdad, Baghdad, Iraq Abstract A series of amic acid derivatives of mefenamic acid were synthesized with the aim of inhibitting topical gastrointestinal toxicity of mefenamic acid. The key intermediate amic acid (III) was prepared from the reaction of acid hydrazid of mefenamic acid(II) with phthalic anhydrides in dry actone. The new type of imide compound (IV) was dehydrated the amic acid(III) with acetic anhydrous and sodium acetate. The esterification of hydroxyl groups of amic acid (III) produce corresponding ester(V), which was condensed with hydrazine hydrate to give acid hydrazide (VI), then the later compound reacted with syringaldehyde in dry benzene to yield new schiff base (VII). The new derivatives containing heterocyclic unit (VIII)- (X), four and five, member ring were successfully formed such as azetidin-2-one, thiazolidin-4-one, and,imidazolidin-4-one. The structures of the synthesized compounds were confirmed using FTIR,1 HNMR, Mass and CHN-S. The antibacterial activities of some synthesized compounds were screened and showed a highest or low inhibition against Staph.aureus (G+), Bacillus subtilisa (G+), Klebsiella pneumoniae (G-), and E.coli (G-). Also, The cytotoxic effect of different concentrations of some the synthesized compounds was tested against MCF-7 cell line (human breast carcinoma cells) and positive results were obtained for some of them, which encouraged us to study the toxicity using living organisms (mice) to evaluate its acute toxicity and proved the resules of non-toxicity of the derivatives. Keywords: Mefenamic acid, imidazolidin-4-one, antibacterial activities, MCF-7 cell line, acute toxicity study. Introduction for different applications, including the presence of effective anti-cancer drugs, antimicrobial, inflammatory Mefenamic acid is one of the anthranilic acid and cytotoxic activities[2]. derivatives class of non-steroidal anti-inflammatory drugs (NSAID) ) is thought to be due to their interference Amic acid and its derivatives have been extremely with prostaglandin biosynthesis, and is used to treat used in drug industry, advanced materials and strong analgesic and antiinflammatory agents in the biologically active heterocycles. In fact, amic acid treatment of degeneration of joint cartilage, rheumatoid carrying suitable position of carboxylic group are prime [1] arthritis and musculosketal disease . precursors for synthesis of heterocyclic derivatives[3]. The general view in the literature shows that A large number of heterocyclic compounds have been mefenamic acid undergoes a number of reactions, this explored for developing pharmaceutically molecules. has been used in the preparation of many compounds Among this the derivatives: azetidin-2-one (β-lactam), containing heterocyclic moiety of therapeutic molecules thiazolidin-4-one, and imidazolidin-4-one, have been playing an important function in the pharmaceutical chemistry [4]. This study is aimed at synthesis new Corresponding Author: active molecules with fewer side effects that can be Muna S. Al-rawi, successfully used as drugs, the cytotoxic effect and non- Assistant Professor, toxicity proved the resules of this derivatives. E-mail: [email protected] Indian Journal of Forensic Medicine & Toxicology, January-March 2020, Vol. 14, No. 1 643 Experimental Shimadzo (Ir prestige-21) Fourier Transform Infrared Spectrometer. 1HNMR spectra were recorded on Materials and instruments: Bruker, Ultra Shield (300)MHz, Switzerland and using All solvents and chemicals were purchased from DMSO-d6, and CDCl3 with reference to TMS as internal Sigma- Aldrich, and GCC Chemicals company. reference. Elemental micro-analyses were carried out Melting points were recorded using electrothermal using an EuroEA Analyzer. Mass spectra of compounds melting point apparatus and are uncorrected. The were measured by Electron Impact (EI) 70eVmass using FTIR spectrums were registered using KBr discs on a MS Model: 5973 spectrometer. Synthetic Procedures The routes for synthesis new derivatives as depending on to the Scheme (1): HN O HN HN O Methanol O NH2NH2.H2O H2N HO H3CO HN H2SO4 (I) (II) Phthalic anhydride acetone O HN OH O HN O O anh.(CH CO) O H 3 2 N , N CH3COONa H N NH (IV) O (III) O H SO Methanol2 4 OCH3 O O HN H N N H O (V) Cl Ar NH NH H O C 2 2. 2 N O NH2 HN HN O O O HN O HN H H N N N N ClCH COCl H H 2 O (VI) O (VIII) Ar ArCHO Ar CH S GAA NH N HN HN HSCH2COOH O O HN O H O O HN N H N N H N O (VII) H O (IX) glycine Ar NH Et3N N HN O O O HN H N N H Ar = 4- OH,3,5-OCH3-C6H2 O (X) 644 Indian Journal of Forensic Medicine & Toxicology, January-March 2020, Vol. 14, No. 1 Scheme (1): The synthetic route for target Calcd. for C23H19N3O3: C, 71.68; H, 4.93; N, 10.90; derivatives(I)-(X) Found: C, 71.98; H, 5.11; N, 11.03. Preparation of methyl 2-(2,3-dimethylanilino) Synthesis of methyl 2-(2-(2-((2,3-dimethylphenyl) benzoate (I) amino) benzoyl) hydrazine -1-carbonyl) benzoate (V): This compound (I)was prepared following the procedure described by Lit. [5] yield 80%; m.p(96-98)0C. A mixture of compound (III) (4.03 g, 0.01mol), absolute methanol 30mL and H2SO4 5.4 mL was refluxed Preparation of 2-(2,3-dimethylphenylamino) 6 hrs. After cooling washed the mixture with NaHCO3 benzohydrazide (II) solution, The resulting of a white crystals solid was This compound(II) was prepared following the filtered off, washed with water, dried and recrystallized procedure described by Lit. [5]. yield 78%,; m.p (118- by ethanol to give compound (V), yield 71%; mp ( o -1 120)ºC. 137-139) C; FTIR (ν ,cm ): 3330-3309 (NH), 2987 (C-H arom.), 2939-2922(C-H aliph.), 1732, 1685, 1657 Synthesis of 2-(2-(2-((2,3-dimethylphenyl)amino) (C=O), and 1255 (C-O); 1H NMR (δ ppm): 2.08 (s, 3H, benzoyl)hydrazine-1-carbonyl ) benzoic acid(III) CH3), 2.27 (s, 3H, CH3),3.86(s,3H,OCH3), 6.66-8.09 (m,11H,Ar-H), 9.66,and 9.18 for (s,1H,NH); Elemental In a flask with magnetic stirrer, a solution of analysis for this compound : Calcd. for C24H23N3O4: C, (2.55g, 0.01 mol) of acid hydrazide (II) in 20 mL of 69.06; H, 5.51; N, 10.07; Found: C, 69.45; H, 5.80; N, acetone was dripped into a solution of (1.48g, 0.01 10.30. mol) phthalic anhydride in 20 mL of acetone for 30 min at room temperature. Stirring was continued for 5 hrs. Synthesis of N’-(2-((2,3-dimethylphenyl) amino) The brown solid precipitate was filtered, washed, dried benzoyl) phthalohydrazide (VI): and recrystallized from ethanol to give a new amic acid [III], yield 74% , m.p (167-169)o C; FTIR (ν ,cm-1): A mixture of ester compound (V) (4.17gm,0.01mol), 3392-2571(OH), 3340-3309 (NH), 3012 (C-H arom.), was dissolved in absolute ethanol 3mL. hydrazine 2974-2912(C-H aliph.), 1712, 1653 (C=O), and 1255 hydrate(0.5gm,0.01 mol) was added slowly and the 1 mixture was refluxed for 6hrs. The mixture was cooled (C-O); H NMR (δ ppm): 2.09 (s, 3H, CH3), 2.28 (s, and the pale yellow solid was filtered, then used ethanol 3H, CH3), 6.66-8.08 (m,11H,Ar-H), 9.45, 7.91,and 7.58 for (s,1H,NH), 12.06(s, 1H, OH, broad); mass spectra to recrystallized, yield 70%, m.p ( 158-160)°C, FTIR (ν -1 (relative intensity%): m/z=403(5), 223 (75), 178(70), ,cm ): 3305-3145(NH2,NH), 3001 (C-H arom.), 2941- 1 75(100), 104(68), 51(25):Elemental analysis: Calcd. 2822(C-H aliph.), 1660,1639(C═O amide); H NMR (δ ppm): 2.11 (s, 3H, CH3), 2.28 (s, 3H, CH3), 6.56- for C23H21N3O4: C, 68.48; H, 5.21; N, 10.42; Found: C, 68.18; H, 5.41; N, 10.73. 8.05 (m,11H,Ar-H),11.13, 9.18,and 8.13(s,1H,NH); Elemental analysis: Calcd. for C23H23N5O3: C, 66.18; H, Synthesis of 2-((2,3-dimethylphenyl)amino) -N- 5.51; N, 16.78; Found: C, 66.70; H, 5.78; N, 17.01. (1,3-dioxoisoindolin-2-yl) benzamide (IV) Synthesis of (Z)-N’1-(2-((2,3-dimethylphenyl) A mixture of 5 mL acetic anhydride and (0.82g , amino) benzoyl) - N’2-(4-hydroxy - 3,5- 0.01mol) anhydrous sodium acetate was allowed to dimethoxybenzylidene) phthalohydrazide (VII) dropping with stirring to a solution of amic acid(III) (4.03 g, 0.01 mol) in 10 mL ethanol for1hrs. The A mixture of new compound (VI)(4.17g, 0.01 mol) , resulting mixture was refluxed over water path for Syringaldehyde (1.82g, 0.01mol) with EtOH 15 mL and 3hr. The reaction poured into ice water, the pale beige four drops of GAA glacial acetic acid was refluxed for precipitated was collected filtered and washed with 6hrs, cooled after that filtered the product and crystallized ice water and recrystallization from ethanol, yield from ethanol,dark yellow powder, yield 70% , m.p. (150- -1 70% , mp. (188-190)oC; FTIR (ν ,cm-1): 3344 (NH), 152)°C, FTIR (ν ,cm ): 3548(OH), 3469-3344(NH), 2978 (C-H arom.), 2885-2735(C-H aliph.), 1747, 1645 3016 (C-H arom.), 2968-2935(C-H aliph.), 1651(C═O 1 (C=O), and 1238 (C-O); 1H NMR (δ ppm): 2.09 (s, amide), 1626(C=N); HNMR(δ,ppm,CDCl3): 2.10 (s, 3H, CH3), 2.29 (s, 3H, CH3), 2.51(s, 1H,OH) , 3.84 (s,6H, 3H, CH3), 2.27 (s, 3H, CH3), 6.66-8.06 (m,11H,Ar- H),9.57(s,1H,NH), 8.14(s,1H,NH); Elemental analysis: OCH3),6.68-8.58 (m,13H,Ar-H),7.32(s,1H,CH-N) Indian Journal of Forensic Medicine & Toxicology, January-March 2020, Vol.
Load more

Recommended publications
  • Granisetron "Vianex"
    EU‐RISK MANAGEMENT PLAN GRANISETRON VIANEX® 1 MG/ML, SOLUTION FOR INJECTION/ INFUSION precautionary measure, breast‐feeding should not be advised during treatment with Granisetron “Vianex”. Legal Status: Prescription only product. VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Nausea and vomiting associated with chemotherapy and radiotheraphy: One of the most distressing symptoms for patients undergoing both surgery and chemotherapy is nausea and vomiting. These symptoms have a significant impact on quality of life and can lead to malnutrition, inability to respond to treatment and an increased length of hospitalization. Emesis is more commonly associated with chemotherapeutic agents; however, radiation‐induced nausea and vomiting (RINV) can affect a significant proportion of patients, depending on the treated area, dose fractionation, and volume of radiotherapy. The relative risk for developing nausea and vomiting with chemotherapy ranges from 30 to 90% and is dependent upon the chemotherapeutic agent used. Relative risk for nausea and vomiting with radiation therapy is approximately 40%.2,3,4,5 Post‐operative nausea and vomiting Postoperative nausea and vomiting (PONV) is a major source of patient dissatisfaction and is the leading cause of discharge delays and unanticipated postsurgical hospital admissions. In the absence of pharmacological treatment, the rate of PONV is approximately 30% in general population, and can be as high as 70% in patients at highest risk. Several risk factors as surgery type, female gender, non‐smoker status, history of postoperative nausea and vomiting or motion sickness and post‐operative opioid use have been acknowledged. Additionally, post‐ operative vomiting (POV) occurs twice as frequently in children as in adults, increasing until puberty and then decreasing to adult incidence rates.
    [Show full text]
  • Synthesis and Pharmacological Evaluation of Fenamate Analogues: 1,3,4-Oxadiazol-2-Ones and 1,3,4- Oxadiazole-2-Thiones
    Scientia Pharmaceutica (Sci. Pharm.) 71,331-356 (2003) O Osterreichische Apotheker-Verlagsgesellschaft m. b.H., Wien, Printed in Austria Synthesis and Pharmacological Evaluation of Fenamate Analogues: 1,3,4-Oxadiazol-2-ones and 1,3,4- Oxadiazole-2-thiones Aida A. ~l-~zzoun~'*,Yousreya A ~aklad',Herbert ~artsch~,~afaaA. 2aghary4, Waleed M. lbrahims, Mosaad S. ~oharned~. Pharmaceutical Sciences Dept. (Pharmaceutical Chemistry goup' and Pharmacology group2), National Research Center, Tahrir St. Dokki, Giza, Egypt. 3~nstitutflir Pharmazeutische Chemie, Pharrnazie Zentrum der Universitilt Wien. 4~harmaceuticalChemistry Dept. ,' Organic Chemistry Dept. , Helwan University , Faculty of Pharmacy, Ein Helwan Cairo, Egypt. Abstract A series of fenamate pyridyl or quinolinyl analogues of 1,3,4-oxadiazol-2-ones 5a-d and 6a-r, and 1,3,4-oxadiazole-2-thiones 5e-g and 6s-v, respectively, have been synthesized and evaluated for their analgesic (hot-plate) , antiinflammatory (carrageenin induced rat's paw edema) and ulcerogenic effects as well as plasma prostaglandin E2 (PGE2) level. The highest analgesic activity was achieved with compound 5a (0.5 ,0.6 ,0.7 mrnolkg b.wt.) in respect with mefenamic acid (0.4 mmollkg b.wt.). Compounds 6h, 61 and 5g showed 93, 88 and 84% inhibition, respectively on the carrageenan-induced rat's paw edema at dose level of O.lrnrnol/kg b.wt, compared with 58% inhibition of mefenamic acid (0.2mmoll kg b.wt.). Moreover, the highest inhibitory activity on plasma PGE2 level was displayed also with 6h, 61 and 5g (71, 70,68.5% respectively, 0.lmmolkg b.wt.) compared with indomethacin (60%, 0.01 mmolkg b.wt.) as a reference drug.
    [Show full text]
  • Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: a PET Study in Conscious Monkeys
    Neuropsychopharmacology (2013) 38, 2666–2674 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: A PET Study in Conscious Monkeys 1 1 1 1 1 Shigeyuki Yamamoto , Hiroyuki Ohba , Shingo Nishiyama , Norihiro Harada , Takeharu Kakiuchi , 1 ,2 Hideo Tsukada and Edward F Domino* 1 2 Central Research Laboratory, Hamamatsu Photonics KK, Hamakita, Japan; Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA Subanesthetic doses of ketamine, an N-methyl-D-aspartic acid (NMDA) antagonist, have a rapid antidepressant effect which lasts for up to 2 weeks. However, the neurobiological mechanism regarding this effect remains unclear. In the present study, the effects of subanesthetic doses of ketamine on serotonergic systems in conscious monkey brain were investigated. Five young monkeys 11 underwent four positron emission tomography measurements with [ C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)benzoni- 11 trile ([ C]DASB) for the serotonin transporter (SERT), during and after intravenous infusion of vehicle or ketamine hydrochloride in a 11 dose of 0.5 or 1.5 mg/kg for 40 min, and 24 h post infusion. Global reduction of [ C]DASB binding to SERT was observed during ketamine infusion in a dose-dependent manner, but not 24 h later. The effect of ketamine on the serotonin 1A receptor (5-HT1A-R) and dopamine transporter (DAT) was also investigated in the same subjects studied with [11C]DASB. No significant changes were observed in either 5-HT -R or DAT binding after ketamine infusion. Microdialysis analysis indicated that ketamine infusion transiently increased 1A serotonin levels in the extracellular fluid of the prefrontal cortex.
    [Show full text]
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE in PETS Introduction Pathophysiology/Etiology to That Observed in Dogs
    VETTALK Volume 15, Number 04 American College of Veterinary Pharmacists THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE IN PETS Introduction Pathophysiology/Etiology to that observed in dogs. It can be The moving topic of this Vet Talk As with most diseases in the veteri- due to a trichobezoar, dehydration, newsletter will be prokinetic medica- nary world, the etiology and patho- obesity, old age, diabetes, immobility, tions. The availability of information physiology of constipation are varied pain from trauma to the low back, on the many prokinetic agents is var- depending on the species being dis- bladder infection, or an anal sac infec- ied at best so an overall consensus of cussed, where in their gastrointestinal tion. In cases that are more chronic, prokinetic medications will be as- tract the problem is occurring, and underlying disease such as colitis or sessed in this article, hopefully giving any accompanying comorbid condi- Irritable Bowel Syndrome (IBS) may better insight to practitioners about tions. be the culprit. On the other hand, the which agents to use in their patients. cause may be idiopathic which is Canines: In man’s best friend, consti- frustrating for both veterinarian and Prevalence pation has many origins. A dog’s patient since this form is most diffi- Chronic constipation and gastroin- digestive tract itself is complex but cult to treat. testinal stasis are highly debilitating ultimately the mass movements and conditions that not only affect human haustral contractions from the large Equines: Despite their large size, patients but our four legged patients intestine (colon), propel feces into the horses have incredibly delicate diges- as well! Though this condition is rectum stimulating the internal anal tive systems.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Exploring the Cocrystallization Potential of Urea and Benzamide
    JMolModel (2016) 22:103 DOI 10.1007/s00894-016-2964-6 ORIGINAL PAPER Exploring the cocrystallization potential of urea and benzamide Piotr Cysewski1 & Maciej Przybyłek1 & Dorota Ziółkowska 2 & Karina Mroczyńska2 Received: 14 November 2015 /Accepted: 14 March 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract The cocrystallization landscape of benzamide and defined by excess thermodynamic functions, and all known urea interacting with aliphatic and aromatic carboxylic acids cocrystals are outside of this range belonging to the third or was studied both experimentally and theoretically. Ten new fourth quartile. On the contrary, such a simple separation of cocrystals of benzamide were synthesized using an oriented positive and negative cases of benzamide miscibility in the samples approach via a fast dropped evaporation technique. solid state is not observed. The difference in properties be- Information about types of known bi-component cocrystals tween urea and benzamide R2,2(8) heterosynthons is also augmented with knowledge of simple binary eutectic mixtures documented by alterations of substituent effects. was used for the analysis of virtual screening efficiency Intermolecular interactions of urea with para substituted among 514 potential pairs involving aromatic carboxylic acids benzoic acid analogues are stronger compared to those of interacting with urea or benzamide. Quantification of intermo- benzamide. Also, the amount of charge transfer from amide lecular interaction was achieved by estimating the excess ther- to aromatic carboxylic acid and vice versa is more pronounced modynamic functions of binary liquid mixtures under for urea. However, in both cases, the greater the electron with- supercooled conditions within a COSMO-RS framework.
    [Show full text]
  • United States Patent (19) 11 4,360,518 Rovee Et Al
    United States Patent (19) 11 4,360,518 Rovee et al. 45) Nov. 23, 1982 54 TOPICAL ANTI-INFLAMMATORY DRUG Primary Examiner-Stanley J. Friedman THERAPY . 57) ABSTRACT 75) Inventors: David T. Rovee, Bridgewater; John A pharmaceutical composition for topical treatment of R. Marvel; James A. Mezick, both of cutaneous disorders or disruptions characterized by East Brunswick, all of N.J. skin inflammation or hyperproliferative epidermal ac 73) Assignee: Johnson & Johnson, New Brunswick, tivity comprises the combination of a topically active N.J. anti-inflammatory corticosteroid and a non-steroidal 21 Appl. No.: 244,569 anti-inflammatory agent which is an inhibitor of prosta glandin synthetase selected from the group consisting of 22 Filed: Mar. 17, 1981 the hydratropic acid derivatives; acetylsalicylic acid; the pyrazolone derivatives; the fenamic acid deriva Related U.S. Application Data tives; the aroyl-substituted pyrroles and the substituted 60) Division of Ser. No. 64,311, Aug. 6, 1979, abandoned, arylacetohydroxamic acids in a pharmaceutically ac which is a division of Ser. No. 788,453, Apr. 20, 1977, ceptable topical vehicle. Treatment of above cutaneous Pat. No. 4,185, 100, which is a continuation-in-part of disorders may also be effected by concurrent therapy Ser. No. 685,942, May 13, 1976, abandoned. using separate applications of corticosteroid and non 51) Int. Cl. ...................... A61K 31/19; A61K 31/56 steroid. (52) U.S. Cl. ..................................... 424/240; 424/317 58) Field of Search ................................ 424/317, 240 18 Claims, No Drawings 4,360,518 1 2 Ziboh, V. A. and Snyder, D. S. 1974 Naturally occur TOPICAL ANTI-NFLAMMATORY ORUG ring and synthetic inhibitors of prostaglandin synthetase THERAPY of the skin.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,221,377 B1 Meyer (45) Date of Patent: Apr
    USOO6221377B1 (12) United States Patent (10) Patent No.: US 6,221,377 B1 Meyer (45) Date of Patent: Apr. 24, 2001 (54) ADMINISTRATION MEDIA FOR (56) References Cited ANALGESIC, ANTI-INFLAMMATORY AND ANT-PYRETC DRUGS CONTAINING FOREIGN PATENT DOCUMENTS NITROUS OXDE AND PHARMACEUTICAL 2 277 264 10/1994 (GB). COMPOSITIONS CONTAINING SUCH MEDIA AND DRUGS OTHER PUBLICATIONS (75) Inventor: Petrus Johannes Meyer, Randburg Chemical ABstracts AN 1985:464783, Hertz et al., Jan. (ZA) 1985.* Chemical Abstracts AN 1978:44978, Berkowitz et al., Jan. (73) Assignee: Pitmy International N.V., Bonaire 1977.* (NL) International Publication No. WO93/25213, published Dec. 23, 1993. (*) Notice: Subject to any disclaimer, the term of this Mikrochim. Acta, vol. 2, No. 5-6, 1980 pp. 464–474, Stahl patent is extended or adjusted under 35 et al., Extraction of natural Substances using Supercritical U.S.C. 154(b) by 0 days. and liquified gases. (21) Appl. No.: 09/068,543 Reynolds J.E.F. et al., “Martindale', 1989, The Pharmaceu tical Press. (22) PCT Filed: Nov. 13, 1996 Science, vol. 194, No. 4268, 1976, pp. 967–968, Berkowitz (86) PCT No.: PCT/IB96/01366 et al., "Nitrous oxide “analgesia': resemblance to opiate action'. S371 Date: May 13, 1998 Steinegger et al., “Lehrbuch der Pharmakognosie und Phy S 102(e) Date: May 13, 1998 topharmazie', Edition 4, 1988. (87) PCT Pub. No.: WO97/17978 * cited by examiner PCT Pub. Date: May 22, 1997 Primary Examiner Jyothsna Venkat (30) Foreign Application Priority Data ASSistant Examiner-Grace Hsu (74) Attorney, Agent, or Firm-Arent Fox Kintner Plotkin Nov. 13, 1995 (ZA) ...................................................
    [Show full text]
  • The Alcohol Withdrawal Syndrome
    Downloaded from jnnp.bmj.com on 4 September 2008 The alcohol withdrawal syndrome A McKeon, M A Frye and Norman Delanty J. Neurol. Neurosurg. Psychiatry 2008;79;854-862; originally published online 6 Nov 2007; doi:10.1136/jnnp.2007.128322 Updated information and services can be found at: http://jnnp.bmj.com/cgi/content/full/79/8/854 These include: References This article cites 115 articles, 38 of which can be accessed free at: http://jnnp.bmj.com/cgi/content/full/79/8/854#BIBL Rapid responses You can respond to this article at: http://jnnp.bmj.com/cgi/eletter-submit/79/8/854 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at service the top right corner of the article Notes To order reprints of this article go to: http://journals.bmj.com/cgi/reprintform To subscribe to Journal of Neurology, Neurosurgery, and Psychiatry go to: http://journals.bmj.com/subscriptions/ Downloaded from jnnp.bmj.com on 4 September 2008 Review The alcohol withdrawal syndrome A McKeon,1 M A Frye,2 Norman Delanty1 1 Department of Neurology and ABSTRACT every 26 hospital bed days being attributable to Clinical Neurosciences, The alcohol withdrawal syndrome (AWS) is a common some degree of alcohol misuse.5 Despite this Beaumont Hospital, Dublin, and management problem in hospital practice for neurologists, Royal College of Surgeons in substantial problem, a survey of NHS general Ireland, Dublin, Ireland; psychiatrists and general physicians alike. Although some hospitals conducted in 2000 and 2003 indicated 2 Department of Psychiatry, patients have mild symptoms and may even be managed that only 12.8% had a dedicated alcohol worker.6 In Mayo Clinic, Rochester, MN, in the outpatient setting, others have more severe addition, few guidelines exist promoting the USA symptoms or a history of adverse outcomes that requires initiation of clear and uniform AWS treatment 7–9 Correspondence to: close inpatient supervision and benzodiazepine therapy.
    [Show full text]
  • Imidazol-1-Ylethylindazole Voltage-Gated Sodium Channel
    Article pubs.acs.org/jmc Terms of Use CC-BY Imidazol-1-ylethylindazole Voltage-Gated Sodium Channel Ligands Are Neuroprotective during Optic Neuritis in a Mouse Model of Multiple Sclerosis Lorcan Browne,† Katie Lidster,‡ Sarah Al-Izki,‡ Lisa Clutterbuck,† Cristina Posada,† A. W. Edith Chan,† Dieter Riddall,† John Garthwaite,† David Baker,‡ and David L. Selwood*,† † Biological and Medicinal Chemistry, Wolfson Institute for Biomedical Science, University College London, Gower Street, London WC1E 6BT, United Kingdom ‡ Neuroimmunology, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom *S Supporting Information ABSTRACT: A series of imidazol-1-ylethylindazole sodium channel ligands were developed and optimized for sodium channel inhibition and in vitro neuroprotective activity. The molecules exhibited displacement of a radiolabeled sodium channel ligand and selectivity for blockade of the inactivated state of cloned neuronal Nav channels. Metabolically stable analogue 6 was able to protect retinal ganglion cells during optic neuritis in a mouse model of multiple sclerosis. ■ INTRODUCTION Voltage-gated sodium (Nav) channels are the fundamental generators of electrical impulses (action potentials) in the membranes of excitable cells. A number of clinically used drugs ff exert their therapeutic e ects through Nav. These drugs are primarily used in the treatment of central nervous system (CNS) disorders, such as epilepsy and neuropathic pain, but are increasingly being scrutinized as potential treatments for neurodegenerative conditions occurring acutely, such as in ischemic stroke, or chronically, as in multiple sclerosis (MS).1 Phenytoin 1 was one of the first antiepileptics developed (Figure 1).
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]